Active Ingredient(s): Zanubrutinib
FDA Approved: * November 14, 2019
Pharm Company: * BEIGENE
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Brukinsa Overview

Zanubrutinib, sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL).[1][4][5][6] Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor.[1] It is given by mouth.[1] It was approved for medical use in the United States in November 2019.[7]&...

Read more Brukinsa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Brukinsa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 80mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Brukinsa: (1 result)

Sorted by National Drug Code
  • 72579-011 Brukinsa 80 mg Oral Capsule, Gelatin Coated by Beigene USA, Inc.

Other drugs which contain Zanubrutinib or a similar ingredient: (1 result)